Valuation: CURE BIOT

Market Cap 5.79M 5.09M 4.73M 4.34M 8.16M 558M 8.28M 56.19M 21.95M 274M 21.75M 21.28M 948M P/E 2023
-2.42x
P/E 2024 -3.29x
Enterprise Value 8.71M 7.65M 7.12M 6.53M 12.27M 839M 12.46M 84.49M 33.01M 412M 32.7M 32M 1.43B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.96%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 73 10/02/2021
Chief Executive Officer - -
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 74 11/05/2022
Director/Board Member 48 30/03/2024
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+53.85%-.--% - - 7.15M
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +5.59%+0.83%+54.97%+107.37% 27.25B
Weighted average by Cap. +0.48%+0.91%+75.32%+136.64%

Financials

2023 2024
Net sales - -
Net income -3.96M -3.48M -3.23M -2.97M -5.57M -381M -5.66M -38.38M -14.99M -187M -14.85M -14.53M -648M -3.44M -3.02M -2.81M -2.58M -4.84M -331M -4.91M -33.32M -13.02M -163M -12.9M -12.62M -562M
Net Debt 2.2M 1.93M 1.8M 1.65M 3.1M 212M 3.15M 21.36M 8.34M 104M 8.27M 8.09M 360M 2.92M 2.56M 2.38M 2.19M 4.11M 281M 4.17M 28.3M 11.06M 138M 10.95M 10.72M 478M
Logo CURE BIOT
Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. It is primarily focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its development pipeline is focused on three therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. IMT504 is an oligodeoxynucleotide (ODN). ODNs are synthetic molecules that stimulate different kinds of cells of immune system of animals and humans.
Employees
-